Colgate-Palmolive: A Long-Term Value Investing Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: Colgate's ceiling lies in "thickening its share within a huge but mature, low-growth existing pie," rather than opening up an entirely new market, and this makes it a steady-compounder rather than a ten-year-five-bagger type of stock. Baillie Gifford's LTGG favors companies that are "creating new markets"; measured by that yardstick, CL is not outstanding on the ceiling dimension, and this must be honestly acknowledged.

  First, look at how big the pie itself is and how slow its growth is. In FY2025 the company had global net sales of about $20.382 billion (+1.4%), and on the report's basis, over 2020-2025 five-year net sales grew from $16.471 billion to $20.382 billion, a compound growth rate of only about 4.3%. Oral care, personal care, and home care are essentially staple consumption; global penetration has long been very high, the industry as a whole roughly tracks population and inflation in a mild expansion, and there is no "zero-to-one" incremental space. This is a pie that has been sliced for over a hundred years.

  Next, look at CL's position within the pie: it is already the biggest slice. The company leads globally in its most core oral-care categories: in 2025, global toothpaste share was about 41.2% and manual toothbrush about 32.4% (year-to-date basis). With share already this high, it means the room to "enlarge the pie by grabbing share" is compressed; every additional point above 41% becomes harder, and the report lists "toothpaste share falling below 38-39%" as the most critical moat warning line, rather than treating "pushing share to 50%" as a growth script.

  The one with relatively structural incremental growth is pet nutrition (Hill's), but it too is enlarging an existing pie rather than creating a new market. Hill's benefits from the long-term "pet humanization + premiumization" trend; Q1 2026 net sales were about $1.2 billion (+6.7%), 22% of total revenue, and its growth is indeed higher than the company overall; but pet food is a mature global market long dominated by Mars and Nestlé Purina, and Hill's penetrates the prescription-diet/scientific-formula niche, which amounts to "thickening an existing premium pie" and hardly counts as opening a brand-new category.

  One-sentence framework judgment: CL's ceiling is high enough (200+ countries, several billion daily consumers' essential needs), but its growth ceiling is very low; it is a "stable hegemon of an existing pie," not a "creator of new markets." For investors seeking a ten-year-five-bagger blue-sky story, it is inherently disadvantaged on this dimension; for long-term owners who want predictable cash flow, it remains a plus. The report ultimately assigns a "Watch" rating and characterizes value release as "the long-term compounding of share, pricing, cash flow, and dividends," consistent with this judgment.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion: almost impossible. Doubling CL's revenue over the next five years (about 15% annualized) is a fantasy relative to its actual growth; the real growth rate is mid-single-digit organic growth, mildly driven by "price" and "volume," with almost no new-business relay, so this Baillie Gifford dimension clearly falls short. This is not harsh criticism; it is the objective ceiling of a mature consumer-products leader.

  First, calibrate expectations with the most recent real growth. FY2025 net sales were about $20.382 billion, up only +1.4% year over year; on the report's basis the 2020-2025 five-year CAGR was about 4.3%. To double in five years would require lifting this figure from about 4% straight to about 15% and sustaining it for five consecutive years, something CL has never done historically and its categories do not support.

  Next, break down the sources of growth to see the driver structure clearly. Q1 2026 net sales were about $5.324 billion, up +8.4% year over year, but this seemingly impressive figure must be unpacked: organic sales were only +2.9% (volume +1.1%, price +2.2%), while the remaining roughly +5.1% came from FX tailwinds, which are unsustainable and reversible "borrowed growth." Stripping out FX, real operating growth is mid-single-digit, with volume and price each contributing a point or two, and this is the norm.

  • Price: CL demonstrated pricing power in an inflationary environment, Q1 2026 pricing contributed about +2.2%, and price increases in core categories are accepted by consumers. But price increases are a mild, capped contribution and cannot double revenue on their own.
  • Volume: volume recovery is slow, with Q1 2026 volume growth only about +1.1%, and the report notes that Asia (Greater China, India) dragged on organic sales at one point, with emerging-market volumes not being stable.
  • New businesses: largely absent. The one with relatively the most structural incremental growth is Hill's pet nutrition, Q1 2026 +6.7%, and it has completed its premiumization transition (exiting the private-label contract-manufacturing business, causing about a -2.7% drag on organic growth); but Hill's is only about 22% of revenue, and even if it keeps growing at mid-to-high single digits, it cannot drive the whole to double. Skin health (Filorga) is not only not a new engine; in 2025, because results fell below expectations, it took about $794 million of after-tax impairment, a negative.

  Framework judgment: CL's growth is mid-single-digit organic growth "with price as the shield, volume as the support, and FX as the noise," and no single second curve is large enough to drive revenue to double in five years. Treating it as a "doubling growth stock" would be a serious misjudgment; treating it as a steady cash cow that relies on "price increases + Hill's slow compounding + dividend-and-buyback share shrinkage" fits the facts. This is also the fundamental reason the report assigns "Watch" and sets base-case expected annualized return at about 6%-8%: returns come from the compounding of cash flow and dividends, rather than a revenue explosion.

  Jun 11, 2026
• QFive years from now, what will take the baton as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion: CL's most realistic "second curve" is Hill's pet nutrition, which does exist today and is contributing incremental growth; but it is relatively small (about 22% of revenue) and grows only at mid-to-high single digits, too little to carry the weight of "taking the baton as the next main growth engine." Beyond that, the company lacks a visible brand-new growth pole, and the once-highly-anticipated skin health curve has already foundered. This is the reality on Baillie Gifford's "second curve" dimension: it exists, but it is not strong enough.

  An already-existing, verifiable second curve: Hill's. It is real money running, not a mere slide-deck concept: Q1 2026 Hill's net sales were about $1.2 billion, up +6.7% year over year, about 22% of total revenue, with operating profit of about $280 million (+8%). It layers on the long-term structural "pet humanization + premiumization" trend and has completed its strategic premiumization transition: proactively exiting the private-label contract-manufacturing business to focus on scientific formulas and prescription diets. This exit caused about a -2.7% short-term drag on organic growth but bought a higher-quality revenue structure. Prescription diets plus veterinary professional recommendation give it stability higher than ordinary FMCG.

  But its ability to "take the baton" is limited, for three reasons. First, it is too small: a 22% share means that even if Hill's sustains mid-to-high single-digit growth, it is only a marginal pull on the oral/personal/home-care main body that makes up about 78% of revenue, and cannot change the overall mid-single-digit growth center. Second, the track is not a blue ocean: pet food is a mature global market long dominated by Mars and Nestlé Purina, and the report explicitly notes that Hill's still faces share pressure from local brands' "more aggressive marketing and lower prices" in markets such as China. Third, it is essentially still "enlarging an existing premium pie" and not opening a brand-new category, an order-of-magnitude gap from the "new-market-creating second curve" that Baillie Gifford prefers.

  Skin health (Filorga), once treated as a second curve, has already stalled out. The company lowered its skin-health outlook due to "category growth below expectations and weak China performance," and in Q4 2025 took about $794 million of after-tax goodwill/intangible impairment; on the report's basis, the three large impairments in 2021/2022/2025 cumulatively exceed $2.2 billion. Far from taking the baton, this curve became a blemish on capital allocation and dragged down the report's score for management's "capital allocation" item (3/5).

  Framework judgment: CL has a genuinely existing second curve (Hill's), but it is a "high-quality marginal increment," not a "gear-shifting main engine"; the company has no third visible new curve, and has one foundered precedent as a cautionary tale. Therefore, on the question of "who takes the baton five years from now," CL's answer is "still these few old businesses compounding slowly," rather than "a brand-new engine igniting." This aligns with the report's tone of "mature categories, steady compounding, limited reinvestment room."

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: CL's core competitive advantage is "globally leading oral-care brand equity + distribution scale across 200+ countries + funding-the-growth cost-absorption capability," and the moat is real and fairly deep (the report gives 4/5); but over the next three to five years it is more likely to be "stable" than "widening," and some regions and categories even face pressure to narrow. Baillie Gifford values a moat's "forward evolution direction"; CL's direction leans sideways, and this is its key constraint.

  How deep is the moat today: let share and pricing power speak. The hardest piece is the oral-care brand: in 2025, global toothpaste share was about 41.2% and manual toothbrush about 32.4%, and Colgate is the clear global category leader. Brand equity translates into real pricing power and profitability: FY2025 gross margin was about 60.1%, and it can still raise prices in an inflationary environment (Q1 2026 pricing contributed about +2.2%), showing the moat is not a paper concept. In pet nutrition, Hill's adds a layer of "soft switching cost" through veterinary professional recommendation, a second moat.

  But the moat's direction leans toward "stable" rather than "widening," and both the report and the data point to this:

  • Share is already high, with limited upside room. A 41% toothpaste share means the margin for further widening is shrinking; the report lists "toothpaste share falling below 38-39% and not recovering for years" as the most critical moat warning, and the framework itself is "holding a high position" rather than "climbing another step."
  • Retailers' bargaining power is rising, weakening the channel moat. The company itself discloses that large retailers have stronger bargaining power and a stronger first-party data advantage, and lists "retailers holding more first-party data" as a risk; in 2025, sales to Walmart and its affiliates were about 11% of net sales, and channel concentration is a structural pressure.
  • Regional local brands are chipping at the edges. The report notes that in China's pet-food market, local brands are grabbing share with more aggressive marketing and lower prices; local competition and private-label pressure in emerging markets (about 45% of revenue) are also intensifying.
  • Skin health proves the moat has weak spots. In 2025 the skin health business took about $794 million of after-tax impairment, showing CL does not have a wide moat in every category.

  Framework judgment: CL is a textbook case of "a core oral-care moat that is both deep and stable, but overall has almost no upside elasticity in the widening direction." Switching costs are weak-to-moderate (switching costs for ordinary toothpaste consumers are low), network effects are basically absent, and its data advantage is still being overtaken by retailers; all of these seal off the path for the moat to keep widening. By Baillie Gifford's yardstick: this is a "defensive moat" worthy of respect, but not a growth moat that "self-reinforces and widens with scale and network effects." The report assigns "Watch" rather than "Buy," and the flattish moat direction is precisely one of the underlying reasons.

  Jun 11, 2026
• QIf its core business were disrupted, does it have the gene to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  Conclusion: on "treating mistakes and bad news," CL is candid and owns up promptly (such as decisively writing down skin health), which is a strength; but it is essentially a mature consumer-products company that "compounds through stable operations," lacking the Baillie Gifford-sense self-reinvention gene of "rising from the ashes after its core business is disrupted." Its strengths are preserving the status quo and fine-tuning, not amputate-and-rebuild. This is an honest assessment: competent at handling bad news, average at self-reinvention.

  First, look at how it treats mistakes and bad news: CL is not bad on this. The most persuasive case is skin health: the company did not hide it; after results fell below expectations and especially amid China weakness, it lowered its outlook and decisively took about $794 million of after-tax impairment; on the report's basis, the three large impairments in 2021/2022/2025 cumulatively exceed $2.2 billion. This admittedly exposes the original error in M&A judgment, but "owning up promptly and removing impaired assets from the books" is itself an honest attitude, better than stubbornly papering over. Hill's proactively exiting the private-label contract-manufacturing business, sticking to a premium focus even knowing it would drag short-term organic growth by about -2.7%, is also a discipline of "daring to cut low-quality revenue."

  But where to apply a discount is also clear. First, the compensation committee will use discretion to dress up results: when calculating 2025 year-end bonuses, it raised "base-business EPS" by about $0.06 to compensate for tariff effects (these tariffs were unknown when the targets were set). This is not fabrication, but it shows the board will cut management some slack on "external factors," and strict value investors need to keep a discount for this. Second, impairments have recurred (three times), and if "owning up to mistakes" turns into "repeatedly making the same kind of mistake and then owning up," it slides from a virtue into a systemic capital-allocation defect.

  Now consider the implicit premise of this chained question: "the self-reinvention gene when the core business is disrupted." This is CL's relative weak spot. The good thing about categories like toothpaste, soap, and home care is that they are "hard to disrupt" (no violent technological churn), so CL has never been forced into the desperate situation of "core business going to zero, must start over," and thus has had no chance to prove whether it has this gene. Inferring from the available evidence: what CL excels at is incremental improvement (funding-the-growth efficiency gains, category premiumization, regional expansion), not paradigm-level self-disruption. Its one larger "reinvention" attempt in the past, entering skin health via acquisition to open a new growth pole, is precisely what failed and ended in a huge impairment, which is instead counter-evidence of a "relatively weak cross-domain self-reinvention capability."

  Framework judgment: CL is a status-quo-preserving company that is "candid about bad news and proactively cuts low-quality assets, but with a relatively weak self-reinvention gene." Its safety comes from its core categories being "hard to disrupt," rather than from "being able to revive after disruption." For Baillie Gifford, a truly great growth stock should show phoenix-like resilience when its core is hit; CL has never demonstrated this ability, and its only large cross-domain reinvention ended in failure. This aligns with the report giving management "capital allocation 3/5" and an overall "Watch" rating: competent-to-above-average at preserving operations, but breaking-and-rebuilding is not its strong suit.

  Jun 11, 2026
• QDoes management (especially the founder) have a long-term vision and interests deeply bound to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Conclusion: CL's management is a case of "professional-manager-style competent alignment": it has a long-term vision, compensation tied to operating-quality metrics, and a strict ownership policy, but it is not the strongly bound "founder-with-a-heavy-stake, interests-bound-to-the-company's-fate" structure Baillie Gifford most favors; they are willing to make some trade-offs for the long term (such as cutting Hill's low-quality contract-manufacturing revenue), but not so far as daring to sacrifice current profit substantially to bet on the distant future. The report gives "3/5, pass but with a discount," consistent with this.

  Degree of alignment: institutional alignment is in place, but the absolute size of holdings is light. CEO Noel Wallace has been CEO since 2019 and chairman since 2020; the company's ownership policy requires the CEO to hold stock worth 8x annual salary and other named executives 4x annual salary, and discloses that all named executives have met the bar; this set of constraints is good in itself. But the absolute binding is not strong: on the report's basis, as of March 9, 2026 Wallace's total personal beneficial ownership was only about 0.25% and all directors and executives combined about 0.43%. This is "professional manager + equity incentive" alignment, not "founder staking his fortune" alignment. At the current market cap of about $71.98 billion, the personal interest represented by 0.25% is not small, but it is an order of magnitude away from the founder-level heavy stakes Baillie Gifford prefers (often double-digit-percentage holdings, sharing the company's fate).

  Long-term vision: the compensation metrics are reasonably designed and oriented toward long-term operating quality. The company's long-term incentives are tied to relative organic sales growth, relative base-business net income growth, free-cash-flow productivity (FCF productivity of 115.7% for the 2023-2025 performance cycle, as cited by the report), and relative TSR; this is closer to long-term value creation than assessing EPS alone, and deserves credit.

  But "are they willing to sacrifice current profit for five to ten years out?": CL's answer is "willing within limits." Positive evidence: Hill's proactively exited the private-label contract-manufacturing business, sticking to premiumization even knowing it would drag short-term organic growth by about -2.7% (Pet Food Processing report), a trade-off of "sacrificing the present for long-term structure." But where to keep a discount is also clear: first, in 2025 the compensation committee raised "base-business EPS" by about $0.06 to compensate for tariff effects that had not yet occurred, showing the board will smooth current-period results for management and is not entirely indifferent to "good short-term numbers"; second, the company simultaneously maintains large dividends and buybacks (2025 dividends of about $1.823 billion, buybacks of about $1.210 billion, and a new $5 billion buyback authorization), returning large amounts of cash to shareholders rather than aggressively betting on the distant future; this is rational for mature consumer products, but it also means it is not an aggressive growth-style management that "would sacrifice present returns for the long term at any cost."

  Framework judgment: CL's management is "trustworthy, long-term-oriented, and reasonably aligned in interest, but not founder-level strongly bound, with a style leaning toward steady returns rather than aggressive gambles." By Baillie Gifford's yardstick, this is "competent," not "excellent"; it lacks the trait of a founder staking everything on a vision and daring to endure long-term losses in exchange for disruption. Combined with the capital-allocation flaw of repeated impairments, the report's "3/5, with a discount" is fair.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and free of harm to society and regulation?5/10

  A

  Conclusion: if Colgate disappeared tomorrow, consumers would feel "moderate-to-strong" longing: the core brands (Colgate toothpaste, Hill's prescription diets) have real emotional and functional stickiness, but daily-chemical categories as a whole are not hard to substitute, and after disappearing they would be quickly filled by P&G and local brands, leaving no irreparable void; meanwhile its growth model is highly sustainable and barely relies on harming society or regulatory arbitrage, which is a clean plus. On Baillie Gifford's dual test of "indispensability + social/regulatory sustainability," CL scores full marks on the second half and a solid pass on the first.

  Indispensability: by category, the strong and weak are distinct.

  • Strongest is Hill's prescription diets: it has built "soft switching costs" through veterinary professional recommendation and scientific formulas, and pet owners and vets have a real dependence on specific prescription diets; Q1 2026 Hill's +6.7%, about 22% of revenue. If this part disappeared, the substitution friction would be greatest and it would be missed the most.
  • Fairly strong is Colgate toothpaste: global share about 41.2%, used daily by several billion people, with extremely high brand trust; in many emerging markets Colgate is almost synonymous with the word "toothpaste," and the emotional and habitual stickiness is real.
  • Weaker is ordinary personal/home care (soap, body wash, dish detergent): the report self-assesses such switching costs as "weak-to-moderate," and the cost for consumers to switch to P&G, Unilever, or local brands is very low, so after disappearing it would be almost painlessly replaced.

  Overall judgment: CL disappearing would bring "inconvenience and loss of brand affection," but would not create a "functional vacancy"; this is fundamentally different from the "truly indispensable" nature of essential medicines or critical infrastructure. The report setting the moat at 4/5 and switching costs at weak-to-moderate echoes this.

  Social/regulatory sustainability: this is CL's clean and clear-cut side. Its growth model, selling toothpaste, soap, cleaners, and pet nutrition, is inherently a business that improves oral and personal hygiene and benefits public health, with no structure of making money "through addiction, data abuse, regulatory arbitrage, or harming consumers." Growth relies on mild price increases + volume repurchase + share compounding (Q1 2026 organic growth +2.9%, volume- and price-driven), not any anti-social profit model. It has paid dividends continuously back to 1895 and raised the dividend for 63 consecutive years, a company that coexists with society over the long term and has a steady reputation. Regulatory risks are mainly routine operating risks such as product safety, environmental compliance, and cross-border tariffs, not "the business model itself stepping on a regulatory red line."

  Framework judgment: CL is a stock where "the brand has real emotional stickiness but the categories are substitutable, while the business model is highly society-friendly and regulation-sustainable." By Baillie Gifford's dual yardstick: it passes the "does not rely on harming society" test (passes it beautifully), but on "how much would customers miss it" it falls into "would be missed, but can be replaced," failing to reach the top tier of "irreplaceable." This aligns with the report's tone of "good business, strong brands, but a moat that is not top-tier, assigned a Watch rating."

  Jun 11, 2026
• QHow are this business's unit economics (gross margin, incremental returns)? Do they improve or worsen as it scales up? Where does the money it earns go?7/10

  A

  Conclusion: CL's unit economics are excellent and stable: about 60% gross margin, strong and substantial free-cash-flow conversion, and ROIC near 19%, a textbook high-quality consumer-products cash machine; but it is already in a state where "the benefits of scale are essentially fully realized," the incremental returns from growing larger are marginally diminishing, and the money it earns is mainly returned to shareholders (dividends + buybacks) rather than reinvested at high returns. Unit economics is a genuine strength for CL, and the report gives financial quality 4/5.

  Gross margin and earnings quality: both high and stable. FY2025 gross margin was about 60.1%, Q1 2026 about 60.6%, staying around 60% year in and year out; this is structurally high gross margin supported jointly by brand pricing power + funding-the-growth efficiency gains, not stacked up through heavy assets. This means for every additional dollar of product sold, about sixty cents is gross profit, and the unit economics are superb.

  Cash conversion: what it earns is real cash, not accounting profit. FY2025 operating cash flow hit a record of about $4.2 billion, with capex on the report's basis of only about $564 million and FCF of about $3.634 billion. Capex is less than 3% of revenue, showing this business is "capital-light, high-cash-return"; it can keep running on very little reinvestment, core evidence of excellent unit economics. The report also notes that over 2023-2025 FCF was broadly on par with or even higher than net income attributable to the company, so cash quality is solid.

  Incremental returns: high, but the scale dividend is basically exhausted. ROIC is at a high level: the report's relative-valuation table gives CL ROIC of about 18.91%, far above the cost of capital, showing excellent returns on existing capital. But the key constraint is: CL is already a global leader across 200+ countries with 41% share, and the "equally high-return places" it can find for newly invested capital are very limited; this is precisely why it returns large amounts of cash to shareholders rather than reinvesting frantically. In other words, unit economics (existing) are very good, but incremental reinvestment room (marginal) is limited, and the elasticity of "better unit economics as it scales" is no longer large.

  Where the money goes: mainly returns, reinvestment as a supplement, and M&A once stumbled. On the report's basis, FY2025 dividends of about $1.823 billion, buybacks of about $1.210 billion, and a new $5 billion buyback authorization; diluted shares fell from about 859.3 million in 2020 to about 811.1 million in 2025, a roughly 5.6% five-year share shrinkage, so buybacks do have real share-shrinking effect. This is the most rational use of capital for a "mature cash cow with limited reinvestment room." But there is one clear misstep: the money spent on the skin-health acquisition had negative returns, with about $794 million of after-tax impairment taken in 2025 and three impairments cumulatively exceeding $2.2 billion on the report's basis; this shows it does "status-quo-preserving reinvestment (efficiency, share shrinkage, dividends)" well and "offensive reinvestment (cross-domain M&A)" poorly.

  Framework judgment: CL's unit economics are a mature high-quality model of "excellent existing returns, limited incremental returns, mainly cash returns." By Baillie Gifford's yardstick, it scores high on "whether the business itself makes money, and makes it cleanly" (60% gross margin + 19% ROIC + strong FCF), but is not outstanding on the growth sub-question of "the larger the scale, the better the unit economics, with incremental capital able to be reinvested at sustained high returns"; it looks more like a highly efficient cash machine with a capped rev limit. This aligns with the report's overall judgment of "strong cash flow, financial quality 4/5, but limited growth, assigned Watch."

  Jun 11, 2026
• QFor it to five-bag in ten years, which conditions must hold simultaneously? Are these conditions realistic? What expectations does today's price imply?2/10

  A

  Conclusion: CL five-bagging in ten years (about 17% annualized) is almost unrealistic; this would require revenue growth, margins, and the valuation multiple to all leap substantially at the same time, and each of these runs counter to the objective attributes of a "mature consumer-products leader"; today's price of about $90 already implies the expectation of "quality premium + base-case growth largely realized," leaving limited room for upside. This is CL's weakest link on Baillie Gifford's "blue-sky upside imagination" dimension, and must be honestly acknowledged.

  Which conditions must hold simultaneously for a ten-year five-bagger: checking the realism one by one.

  • Revenue must accelerate from mid-single-digit to double-digit: CL's five-year net-sales CAGR is about 4.3%, FY2025 only +1.4%, Q1 2026 organic growth +2.9%. To support a five-bagger, revenue would need to sustain growth far above this for a long time; mature staple consumption has no such engine, unrealistic.
  • Margins must keep expanding substantially: it is already at a high of about 60% gross margin, with upside room sealed off by raw materials, retailer bargaining, and the ceiling on price increases (Q1 2026 gross margin already slipped slightly due to rising raw-material costs), limited room.
  • The valuation multiple must not compress, and preferably should expand: CL currently has a trailing PE of about 34.9, already a high quality premium for a single-digit-growth company. A five-bagger script needs the market to grant a higher multiple, but the more realistic direction is the multiple reverting from a "high-quality-consumer premium" to an "ordinary defensive stock," a compression risk instead.
  • No more capital-allocation mistakes: past 2025 skin-health impairment of about $794 million after-tax, and three impairments cumulatively over $2.2 billion on the report's basis, so history does not support the optimistic assumption of "ten years with zero mistakes."

  Four conditions must hold at the same time, and each departs from reality; stacked together, the probability of a ten-year five-bagger is extremely low. On this basis the report sets base-case expected annualized return at about 6%-8% and optimistic at only 9%-11%, an order of magnitude away from a "five-bagger."

  What expectations does today's price imply? It has already priced in a substantial part of base-case value. The company has a current price of about $89.95 and a market cap of about $71.98 billion, a 52-week range of about $74.55-99.33, sitting in the upper-middle of the range. The report's DCF gives conservative about $63, base case about $95-100, and optimistic about $120-125; the price of about $90 already stands in the upper-waist of the "base-case scenario," meaning the market has already paid most of the money for the base-case script of "core share holding + Hill's mid-to-high single-digit growth + no more large impairments." In other words, buying today is more like "paying a fair price for known high quality" than "buying undervalued growth at a cheap price." The report's relative valuation also confirms this: CL's P/FCF of about 19.25x and EV/EBITDA of about 16.07x are on the expensive side but not a bubble, and the market has fully recognized its quality.

  Framework judgment: CL's conditions for a ten-year five-bagger "each depart from reality and must all hold at once," while today's price already implies base-to-optimistic expectations; the room for upside imagination is thin. By Baillie Gifford's blue-sky yardstick, this is its fatal weakness: what it can offer is stable mid-single-digit annualized returns, and it cannot offer the non-linear upside that changes destiny. The report's "Watch" rating and fair buy price set at $65-75 (clearly below the current price) are precisely a direct reflection of "a good company but a current price that has overdrawn the upside, with an insufficient margin of safety."

  Jun 11, 2026
• QWhy has the market not yet realized all this? Is it that it cannot understand, looks down on it, or cannot see far enough? What would become the "narrative inflection point"?3/10

  A

  Conclusion: for CL, the market has precisely "realized everything": it can understand it, values it highly, and sees far, so it has granted a high quality premium; there is no "undiscovered perception gap" here. The conventional answers to this Baillie Gifford question (cannot understand / looks down / cannot see far) hold in reverse for CL: the market fully prices it, there is no dust-covered alpha, and the narrative inflection point is more likely "downward" than "upward." This is an honest conclusion, not fabricating a "benefit the market has not yet realized" just to fit a growth narrative.

  Why say the market "has realized it all"? Three pieces of evidence.

  • Can understand: CL is a textbook-simple, transparent business, with no complex financial structure and no technology black box, broadly covered and extremely well researched; the sell side maintains a "Buy" consensus with a 12-month target price of about $95.84, understanding has long been saturated, and there is no "mispricing caused by inability to understand."
  • Values it highly: the market has granted it a clear quality premium: trailing PE of about 34.9, a high multiple for a single-digit-growth company, and in the report's relative valuation CL's P/FCF of about 19.25x and EV/EBITDA of about 16.07x are not cheap either. This is "valuing it too highly," not "looking down on it."
  • Sees far: the market has already priced in ahead of time the long-term certainty of "core share holding, Hill's mid-to-high single-digit growth, dividends growing for 63 consecutive years"; a current price of about $89.95 and a market cap of about $71.98 billion already stands in the upper-waist of the report's base-case value (about $95-100). It has seen all the long-term good and paid for it.

  So the report's judgment is: CL is a "high-quality asset fully recognized by the market," not a "bargain ignored by the market"; it classifies CL as "expensive but not a bubble, with the price already reflecting considerable recognition of its quality." Absent a perception gap, what investors get is stability, not excess returns.

  So what would the "narrative inflection point" be? The key: CL's current inflection risk leans downward rather than upward.

  • Downward inflection (warrants more caution): (1) core toothpaste share declining continuously, falling below 38-39% and not recovering for years, which would directly puncture the core narrative of "global oral-care hegemon"; (2) Hill's losing its professional-recommendation advantage or deteriorating gross-margin structure, with the second curve flaming out; (3) another large M&A impairment (following the 2025 skin-health after-tax impairment of about $794 million), cementing "capital-allocation mistakes" from incidental into systemic; (4) valuation reverting from a "high-quality-consumer premium" to an "ordinary defensive stock," which the report notes would send the price back to about $50-60, corresponding to a permanent loss of -35% to -45%.
  • Upward inflection (harder to occur): for the market to re-raise its narrative, CL would need to deliver better-than-expected volume acceleration or a genuinely new growth pole; but mature categories and limited reinvestment room make such a positive inflection hard to happen.

  Framework judgment: CL has no "not yet realized by the market" perception gap to capture; it is a fully priced high-quality defensive asset, and its narrative inflection is more "downside risk" than "upside surprise." By Baillie Gifford's yardstick, this is its fundamental constraint as a growth target: the "price is not cheap" within "good company, good business, bad price," which corresponds precisely to the report's "Watch" rating and its final recommendation to "wait for a price with a better margin of safety, rather than accepting mediocre returns just because it is a good company."

  Jun 11, 2026